D. Oulid-Aïssa

Erlotinib for Frontline Treatment of Advanced Non–Small Cell Lung Cancer: a Phase II Study

Giuseppe Giaccone, Mariëlle Gallegos Ruiz, Thierry Le Chevalier et al. · Clinical Cancer Research · 2006 · 200 citations

The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication

A Béhar, Éric Pujade-Lauraine, Michèle Brun et al. · British Journal of Clinical Pharmacology · 1997 · 72 citations · Full text

Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation

M. C. Launay-Iliadis, René Bruno, Valérie Cosson et al. · Cancer Chemotherapy and Pharmacology · 1995 · 57 citations

Pharmacokinetic Modeling, Nonlinear Mixed-effect Modeling, Medicine +9

Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer

Bengt Glimelius, Raija Ristamäki, Per Pfeiffer et al. · Annals of Oncology · 2002 · 37 citations · Full text

First-line Therapy, Medicine, Pharmacology +7

A phase II study of erlotinib as first-line treatment of advanced non-small cell lung cancer

Giuseppe Giaccone, T. Lechevalier, Nicholas Thatcher et al. · Journal of Clinical Oncology · 2005 · 28 citations

Pathology, Phase Ii Study, First-line Treatment +16